Weight & Metabolic
How Much of the Weight Lost on GLP-1s Is Muscle?
The short answer
Across 35 randomized trials, the median share of total weight loss coming from muscle-related measures was about 28% — but the range was enormous, from roughly 16% to 40% depending on the study. Lifestyle-only weight loss showed the same pattern in nearly half of studies. And no trial measured whether any of it affected strength or physical function.
Quick answers
- What is it?
- How much of the weight lost on GLP-1 drugs is actually muscle rather than fat.
- Why are people interested in it?
- People taking these drugs worry about losing muscle along with fat and want a real number.
- What has actually been studied?
- A 2026 systematic review pooling 35 randomized trials, median 78 participants over 26 weeks, reporting body composition outcomes for liraglutide, semaglutide, tirzepatide, or dulaglutide, compared against lifestyle-only comparator arms.
- How strong is the evidence?
- The median share of weight loss from muscle-related measures was about 28%, but with an enormous range from 16% to 40%, and lifestyle-only weight loss showed comparable losses in nearly half of studies, so the effect isn't unique to these drugs.
- What don't we know yet?
- Whether it affects physical function, since no trial measured grip strength or gait speed, whether the lost tissue is muscle specifically versus fluid, and what happens to the muscle after stopping the drug.
- Where can I read the original research?
- Sources at the bottom of this page: Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review and Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation.
The short answer: A 2026 systematic review pooled 35 randomized trials and found that the median share of total weight loss coming from muscle-related measures was about 28%. But that median hides a very wide spread — individual studies ranged from roughly 16% to 40%. The same review found that people losing weight through lifestyle changes alone showed comparable losses in nearly half of studies. And critically: not one trial measured whether any of this affected strength or physical function.
What the research shows
The number, and why it needs context
Researchers screened 8,102 papers and found 35 randomized controlled trials reporting body composition outcomes for liraglutide, semaglutide, tirzepatide, or dulaglutide. Median trial length was 26 weeks; median size was 78 participants.
Across those trials, the median proportion of total weight loss attributable to muscle-related measures was 28.3%, with an interquartile range of 15.9% to 39.9%.
The reviewers had set a benchmark beforehand — roughly 25% of weight loss coming from fat-free mass is what you would expect from weight loss generally. 65% of the incretin studies exceeded it.
Measurement method mattered:
| Method | Median share from muscle measures | Exceeded benchmark |
|---|---|---|
| BIA or DXA | ~29% (IQR 16.6–43.1%) | 67% |
| CT or MRI | ~25.3% (IQR 16.7–27.2%) | ~two-thirds |
Notice how much tighter the CT/MRI range is. Those are the more precise imaging methods, and they produced less extreme estimates — which suggests some of the alarming high-end numbers may be measurement artifact rather than biology.
The context most coverage leaves out
The same review looked at the comparator arms — people losing weight through lifestyle or placebo rather than drugs. Those groups lost far less weight overall (median −2.5%). But 38% of them also exceeded the muscle-loss benchmark.
That matters. Losing lean mass alongside fat is a general feature of weight loss, not something unique to these drugs. The honest framing is that incretin therapies produce more total weight loss, and therefore more absolute lean mass loss — not that they uniquely destroy muscle.
What the review could not do
The authors could not perform a meta-analysis. Body composition methods and reporting varied too much between studies to pool the numbers statistically. Only 42.9% of the studies were rated at low risk of bias, and only 28.6% had prespecified body composition as a primary outcome — meaning in most of these trials, muscle was a secondary measurement, not the thing the study was built to detect.
What we don't know yet
Whether it affects function. This is the largest gap, and it is remarkable. Across all 35 trials, no study reported objective physical function outcomes — no grip strength, no gait speed, no sit-to-stand testing. We know a number changed on a scan. We do not know whether anyone became measurably weaker.
Whether the lost tissue is muscle specifically. "Fat-free mass" and "lean soft tissue" include water, glycogen, connective tissue, and organ mass. Rapid weight loss shifts fluid substantially. How much of the measured decline is contractile muscle is not resolved by these methods.
Whether protein intake or resistance training changes the outcome. Review articles propose protein targets and structured resistance training for people on these drugs, but those proposals are extrapolated from general weight-loss research. They have not been tested against a control group in this specific population.
What happens to the muscle after stopping. No trial has tracked whether lean mass recovers, stays down, or is replaced disproportionately by fat when treatment ends.
Who is most at risk. Older adults and people with existing sarcopenic obesity are the obvious concern, but the trials were not powered to answer that.
Sources
- Batsis JA, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Annals of Internal Medicine, 2026;179(7):996–1013. DOI
- Arslan S. Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation. Clinical Nutrition ESPEN, 2026;73:103305. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Weight & Metabolism · Energy & Performance | Evidence Index: semaglutide · tirzepatide · liraglutide · dulaglutide
Sources
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.